Onasemnogene abeparvovec
Zolgensma (onasemnogene abeparvovec) is a gene pharmaceutical. Onasemnogene abeparvovec was first approved as Zolgensma on 2019-05-24. It is used to treat spinal muscular atrophy in the USA. It has been approved in Europe to treat spinal muscular atrophy.
| Trade Name | Zolgensma |
|---|---|
| Common Name | Onasemnogene abeparvovec |
| Indication | spinal muscular atrophy |
| Drug Class |
